Palbociclib, a well-tolerated and effective CDK4/6 inhibitor was initially granted accelerated approval in February 2015, in combination with letrozole for the treatment of estrogen receptor (ER)-positive, HER2-negative advanced breast cancer [19]. The gene discussed is CDK4; the disease is breast cancer.